No Data
No Data
Intellia Therapeutics | 10-K: Annual report
TD Cowen Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Citi Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $14
Analysts' Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)
Intellia Therapeutics Price Target Raised to $14 From $12 at Citi
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Intellia Therapeutics (NTLA)
DD07 : is it still an entry position